Suven Pharmaceuticals Renamed as Cohance Lifesciences
ECONOMY & POLICY

Suven Pharmaceuticals Renamed as Cohance Lifesciences

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences.

This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics.

The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide.

"The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world" said Cohance Executive Chairman, Vivek Sharma.

The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation.

The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences. This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics. The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma. The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Next Story
Infrastructure Urban

Hindalco to Invest Up to Rs 80 Billion in FY25 Capex

Hindalco Industries has planned capital expenditure of Rs 75–80 billion for the current financial year, as disclosed in a regulatory filing. Managing Director Satish Pai noted during the Q4 earnings call that this year’s capex guidance ranges between Rs 75 billion and Rs 80 billion. For the previous fiscal year, the company had spent Rs 65 billion on capital expenditure. Pai added that guidance for the next year will be available by the third quarter, as upstream projects begin to take shape. In the March 2025 quarter, consolidated net profit rose by sixty-six per cent to Rs 52.8..

Next Story
Equipment

Mining Gear Sector May Touch Rs 3.75 Trillion by 2030

India’s mining and construction equipment (MCE) sector, currently valued at Rs 1.33 trillion ($16 billion), is projected to grow at a compound annual rate of 19 per cent, reaching Rs 3.75 trillion ($45 billion) by 2030, as per the Confederation of Indian Industry (CII) and Kearney report. The CII-Kearney Vision Report positions India as a future global hub in the MCE sector. With a global market of Rs 1,50,00,000 billion ($18 trillion), the MCE sector supports infrastructure, energy, and industrial growth worldwide, contributing 16 per cent to global gross domestic product. India..

Next Story
Infrastructure Urban

Sanlam Invests in Shriram AMC with 23 Per Cent Stake

South Africa-based Sanlam has invested Rs 1.05 billion for a twenty-three per cent stake in the asset management arm of the Shriram Group. This marks Sanlam’s formal entry into the Indian market. Sanlam, which manages over USD 80 billion in assets, has maintained a partnership with the Chennai-based financial group for more than two decades. With this latest investment, it becomes a co-promoter in Shriram Asset Management Company alongside ShriramCredit Company. As a result, the overall promoter shareholding in the listed entity will rise from 62.55 per cent to 71.17 per cent. Sanl..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?